Advertisement

Der Beitrag des analytischen Biochemikers zur Therapieresistenz der Schizophrenie

  • K. K. Midha
  • J. W. Hubbard
  • P. R. A. May
Chapter
  • 20 Downloads

Zusammenfassung

Man kann drei Gründe, derentwegen ein Patient gegenüber einer konventionellen Therapie mit Dopaminantagonisten resistent sein könnte, identifizieren:
  1. 1.

    Das Medikament und seine psychoaktiven Metaboliten gelangen nicht in das Zentralnervensystem des Patienten.

     
  2. 2.

    Nach langfristiger Behandlung mit Dopaminantagonisten hat der Patient möglicherweise eine medikamentös induzierte Verhaltenstoxizität entwikkelt, die sich wie eine krankheitsbedingte Verhaltens- oder Bewegungsstörung darstellen kann.

     
  3. 3.

    Der Patient gehört möglicherweise zu einer schizophrenen Untergruppe, für die die kontinuierliche Behandlung mit Dopaminantagonisten ungeeignet ist.

     

Diese Arbeit geht einigen Möglichkeiten nach, mit denen der analytische Biochemiker zum Verstehen des Phänomens der Therapieresistenz beitragen kann, das bei jenem Typ von Patienten vorliegt, der trotz einer neuroleptischen Therapie ein ständiges psychiatrisches Sorgenkind bleibt. Zunächst ist es wichtig herauszufinden, ob es einen identifizierbaren Grund für das schlechte Ansprechen des Patienten gibt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literaturverzeichnis

  1. Bowers MB. Central dopamine turnover in schizophrenic syndromes. Arch Gen Psychiatry 1974; 31: 50–54.PubMedCrossRefGoogle Scholar
  2. Cohen BM, Herschel M, Aoba A. Neuroleptic, antimuscarinic and antiadrenergic activity of chlorpromazine, thioridazine and their metabolites. Psychiatry Res 1979; 1: 199–208.PubMedCrossRefGoogle Scholar
  3. Cooper TB, Simpson GM, Haher EJ, Berger P-EE. Butaperazine pharmacokinetics. Arch Gen Psychiatry 1975; 32: 903–905.PubMedCrossRefGoogle Scholar
  4. Costall B, Naylor RJ. Neuropharmacological studies on D-145 (1,3-dimethyl-5-aminoadamantanamine). Psychopharmacology 1975; 43: 53–61.CrossRefGoogle Scholar
  5. Creese I, Snyder SH. A simple and sensitive radioreceptor assay for antischizophrenic drugs in blood. Nature 1977; 270: 180–182.PubMedCrossRefGoogle Scholar
  6. Crow TJ. Molecular pathology of schizophrenia: More than one disease process? Br Med J 1980; 280: 66–68.CrossRefGoogle Scholar
  7. Curry SH. Plasma protein binding of chlorpromazine J Pharm Pharmacol 1970; 22: 193–197.CrossRefGoogle Scholar
  8. Dimasclo A, Bernado D, Greenblatt D, Mander J. A controlled trial of amantadine in drug-induced extrapyramidal disorders. Arch Gen Psychiatry 1976; 33: 599–602.CrossRefGoogle Scholar
  9. Fann W, Lake C. Amantadine vs trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism. Am J Psychiatry 1976; 133: 940–943.PubMedGoogle Scholar
  10. Forsman A, Ohman R. Studies on serum protein binding of haloperidol. Curr Ther Res 1977; 21: 245–255.PubMedGoogle Scholar
  11. Gaddum JH. Drugs antagonistic to 5-hydroxytryptamine In Wolstenholme GW, ed. Ciba foundation symposium on hypertension. Boston: Little Brown, 1954: 75–77. Gelenberg M. The catatonic syndrome. Lancet 1976; 1: 1339–1341.Google Scholar
  12. Gelenberg M, Mandel MR. Catatonic reactions to high potency neuroleptic drugs. Arch Gen Psychiatry 1977; 34: 947–950.PubMedCrossRefGoogle Scholar
  13. Hall K, Yeung Pkf, Midha KK. Decomposition of sulfoxide metabolites of phenothiazine antipsychotics during gas chromatographic analysis. J Chromatogr Biomedical Applications 1982; 231: 200–204.CrossRefGoogle Scholar
  14. Hansen LB, Larsen NE. Metabolic interaction between perphenazine and disulfiram. Lancet 1982; 2: 1472.PubMedCrossRefGoogle Scholar
  15. Hornykiewicz O. Brain catecholamines in schizophrenia — a good case for noradrenaline. Nature 1982; 299: 484–486.PubMedCrossRefGoogle Scholar
  16. Hubbard JW, Cooper JK, Hawes EM, Jenden DJ, May Pra, Martin M, Mckay G, Van Google Scholar
  17. Putten T and Midha KK. Therapeutic Monitoring of Chlorpromazine. I: Pitfalls in Plasma Analysis. Ther Drug Monit 1985; 7: 222–228.PubMedCrossRefGoogle Scholar
  18. Leysen JE, Niemigeers Cje, Tollenaere JP, Laduron PM. Serotonergic component of neuroleptic receptors. Nature 1978; 272: 168–171.PubMedCrossRefGoogle Scholar
  19. Lindenmayer JP, Smith D, Katz A. Radioreceptor assay of neuroleptics in refractory chronic schizophrenic patients. J Clin Psychiatry 1984; 45: 117–119.PubMedGoogle Scholar
  20. Loo Jck, Midha KK, Mcgilveray IJ. Pharmacokinetics of chlorpromazine in normal volunteers. Communications in Psychopharmacology 1980; 4: 121–129.PubMedGoogle Scholar
  21. May Pra, Van Putten T. Plasma levels of chlorpromazine in schizophrenia: A critical review of the literature. Arch Gen Psychiatry 1978; 35: 1081–1087.PubMedCrossRefGoogle Scholar
  22. May RH. Catatonic-like states following phenothiazine therapy. Am J Psychiatry 1959; 115: 1119–1120.PubMedGoogle Scholar
  23. Murphy DL, Wyatt RT. Reduced monoamine oxidase activity in blood platelets from schizophrenic patients. Nature 1972; 238: 225–226.PubMedCrossRefGoogle Scholar
  24. Nakahara T, Hirano M, Uchimura H, et al. Dopamine, serotonin and alphaadrenergic receptor blocking activities in serum and their relationships to prolactin level in schizophrenic patients receiving long term chlorpromazine treatment. Psychopharmacology 1983; 79: 266–270.PubMedCrossRefGoogle Scholar
  25. Nyberg G, Axelson R, Martenson E. Binding of thioridazine and thioridazine metabolites to serum proteins in psychiatric patients. Eur J Clin Pharmacol 1978; 14: 341–350.PubMedCrossRefGoogle Scholar
  26. Opler LA, Kay SR, Vital-Herne J. Combined mesoridazine and amantadine treatment in refractory schizophrenics. Curr Ther Res 1985; 37: 318–325.Google Scholar
  27. Papadopoulos AS, Chand TG, Crammer JL, Laders S. A pilot study of plasma thioridazine and metabolites in chronically treated patients. Br J Psychiatry 1980; 136: 591–596.PubMedCrossRefGoogle Scholar
  28. Petroutka SJ, U’Prichard DC, Greenberg DA, Snyder SH. Neuroleptic drug interactions with norepinephrsne alpha-receptor binding sites in rat brain. Neuropharmacology 1977; 16: 549–556.Google Scholar
  29. Pi EH, Simpson GM. The treatment of refractory schizophrenia: Pharmacotherapy and clinical implications of blood level measurement of neuroleptics. Int Pharmacopsychiatry 1981; 16: 154–161.PubMedGoogle Scholar
  30. Piafsky KF. Disease-induced changes in the plasma binding of basic drugs. Clin Pharmacokinet 1980; 5: 246–262.PubMedCrossRefGoogle Scholar
  31. Randrup A, Munkvad I. Special antagonism of amphetamine-induced abnormal behaviour. Inhibition of stereotyped activity with increase of some normal activities. Psychopharmacology 1965; 7: 416–422.CrossRefGoogle Scholar
  32. Rivera-Calimlim L. Problems in therapeutic blood monitoring of chlorpromazine Ther Drug Monit 1982; 4: 41–49.CrossRefGoogle Scholar
  33. Sakalis G, Chan TL, Gershon S, Park S. The possible role of metabolites in therapeutic response to chlorpromazine treatment. Psychopharmacology 1973; 32: 279–284.CrossRefGoogle Scholar
  34. Smialowska M. The influence of 1,3-dimethyl-5-adamantanamine (D-145) on catecholaminergic neurones of the rat brain: Histofluorescence studies. Pol J Pharmacol Pharm 1976; 28: 259–268.PubMedGoogle Scholar
  35. Stein L, Wise CD. Possible etiology of schizophrenia: Progressive damage to the noradrenergic reward system by 6-hydroxydopamine. Science 1971; 171: 1032–1036.PubMedCrossRefGoogle Scholar
  36. Turano P, Turner WJ, Donato D. Further studies of chlorpromazine metabolism in schizophrenic men. In: Forrest IS, Carr CJ, Usdin E, eds. The phenothiazines and structurally related drugs. New York: Raven Press, 1974: 315–322.Google Scholar
  37. Van Kammen DP, Bunney WE, Docherty JP, Marder SR, Ebert MH, Rosenblatt JE, Rayner JN. d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia. Am J Psychiatry 1982; 139: 991–997.PubMedGoogle Scholar
  38. Verbeeck RK, Cardinal JA, Hill AG, Midha KK. Binding of phenothiazine neuroleptics to plasma proteins. Biochem Pharmacol 1983; 32: 2565–2570.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Fachmedien Wiesbaden 1988

Authors and Affiliations

  • K. K. Midha
    • 1
    • 2
  • J. W. Hubbard
    • 1
    • 2
  • P. R. A. May
    • 1
    • 2
  1. 1.College of PharmacyUniversity of SaskatchewanSaskatoonKanada
  2. 2.Neuropsychiatric InstituteUniversity of CaliforniaLos AngelesUSA

Personalised recommendations